Navigation Links
Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
Date:11/18/2010

SAN DIEGO, Nov. 18, 2010 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced the presentation of new data from the Company's mitochondrial inhibitor program showing activity in chemotherapy-resistant ovarian cancer stem cells.  The data were reported today at the 1st World Congress on Targeting Mitochondria in Berlin.

Ayesha Alvero, M.D., Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, presented data from a pre-clinical study of first-generation compound NV-128 demonstrating its ability to induce mitochondrial instability, ultimately leading to cell death in chemotherapy-resistant ovarian cancer stem cells.

"This study showed for the first time that targeting the mitochondria induces caspase-independent cell death in otherwise chemotherapy-resistant ovarian cancer stem cells," said Dr. Alvero.  "The demonstration that a compound can disrupt cancer cell metabolism by specifically targeting the mitochondria to induce cell death opens anavenue for the development of potential new therapeutics for ovarian cancer patients."

The study further characterized the novel mechanism of action of NV-128, an isoflavone derivative that promotes a state of cellular starvation, resulting in the activation of two independent signalling pathways in cancer cells: 1) the AMPkinase pathway leading to inhibition of the mammalian target of rapamycin (mTOR) complexes and the induction of destructive autophagy; and 2) the MEK/ERK pathway leading to mitochondrial depolarization and DNA fragmentation.

"In addition to this exciting data from Yale, our first-generation compound NV-128 has shown pre-clinical activity against a broad range of cancers, including KRAS-mutant, Tarceva®-resistant non-small cell lung cancer cell lines," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards.

Marshall Edwards has also identified a next-generation compound named NV-344 that appears to be significantly more active than NV-128 in pre-clinical studies. The Company plans to conduct the necessary non-clinical studies to initiate clinical trials of NV-344 in 2011.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's pipeline is derived from an investigational isoflavone technology platform that has generated a number of compounds with anti-proliferative activity in human cancer cell lines. These small molecules have been shown to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival.  The Company's lead programs focus on two families of compounds with related but distinct mechanisms of action. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
2. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
3. Medivir Announces Positive 24-week Interim Data of TMC435 From the ASPIRE Study (C206)
4. GSI Group Inc. Announces John Roush to Become Chief Executive Officer
5. Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
8. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSEs Shareholder Approval Policy
10. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
11. Misonix Announces Achievement of Contract Vendor Status With Select Medical Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... ... Finally, a bruise cream that really works. Originally designed to reduce ... post-surgical treatment plans of a variety of other procedures including, but not limited to, ... bruising and causes a rapid resolution of bruising and inflammatory changes compared to no ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Dr. Seema Daulat, ... Evans Dermatology in the South Lamar location as of July 13, 2016. , Dr. ... School. As a medical student, she regularly volunteered at the Agape Clinic serving Dallas’ ...
Breaking Medicine News(10 mins):